ASH News Daily - Saturday, December 10, 2011 - (Page B-11)

T:10” S:9” INDICATIONS • Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy • Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated. THE FIRST AND ONLY DRUG APPROVED IN BOTH PTCL AND CTCL S:13” RECHARGE THE POSSIBILITIES www.istodax.com Please see Important Safety Information on adjacent page. Please see Brief Summary of full Prescribing Information on following pages. 

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com